Catalyst
Slingshot members are tracking this event:
Novartis (NVS) to present full Phase 3 study data on RTH-258 treating Neurovascular Age-Related Macular Degeneration (AMD) at the American Academy of Ophthalmology Meeting on November 10th, 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| NVS | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 10, 2017
Occurred Source:
https://www.novartis.com/news/media-releases/novartis-brolucizumab-rth258-demonstrates-superiority-versus-aflibercept-key
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Rth-258, Phase 3 Topline Data
